NEW YORK and SYDNEY, Australia, July 26, 2022 - Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), wishes to advise shareholders that in accordance with section 251AA of the Corporations Act, the following information is provided in respect of each resolution considered and voted upon at the General Meeting of Beroni Group Limited held today.
The total number of proxy votes exercisable by proxies validly appointed was 46,928,322 shares from the validly appointed proxies of 19 shareholders. All resolutions were passed by way of a Poll.
Details of proxy votes and Poll in respect of each of the resolutions set out in the Notice of General Meeting and Addendum to Notice of General Meeting are shown in the tabulation below:
-End-
About Beroni Group Limited
Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.
Manner in which securityholder directed the proxy vote (at proxy close
Manner in which votes were cast in person or by proxy on a poll (if applicable)
date)
RESOLUTION
VOTES
VOTES
VOTES
VOTES
FOR
AGAINST
ABSTAIN
VOTES
RESULT
FOR
AGAINST
DISCRETIONARY
DISREGARDED
DISREGARDED
1. CONDITIONAL Issue of OFFER UNITS TO
46,928,322
0
0
0
46,928,322
0
0
Carried
UNDERWRITER
0
2. CONDITIONAL ISSUE OF OVER-ALLOTMENT OFFER
46,928,322
0
0
0
46,928,322
0
0
Carried
UNITS PURSUANT TO UNDERWRITER OPTION
0
3. CONDITIONAL ISSUE OF WARRANTS
46,928,322
0
0
0
46,928,322
0
0
0
Carried
4. CONDITIONAL CONSOLIDATION OF SECURITIES
46,928,322
0
0
0
46,928,322
0
0
0
Carried
5. CONDITIONAL CONSOLIDATION OF SECURITIES
46,928,322
0
0
0
46,928,322
0
0
0
Carried
6. CONDITIONAL CONSOLIDATION OF SECURITIES
46,928,322
0
0
0
46,928,322
0
0
0
Carried
7. CONDITIONAL CONSOLIDATION OF SECURITIES
46,928,322
0
0
0
46,928,322
0
0
0
Carried
8. CONDITIONAL CONSOLIDATION OF SECURITIES
46,928,322
0
0
0
46,928,322
0
0
0
Carried
9. CONDITIONAL WITHDRAWAL OF LISTING ON NSX
46,928,322
0
0
0
46,928,322
0
0
0
Carried
10. AMENDMENT TO CONSTITUTION
46,928,322
0
0
0
46,928,322
0
0
0
Carried
Attachments
Original Link
Original Document
Permalink
Disclaimer
Beroni Group Ltd. published this content on 26 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2022 06:38:01 UTC.
Beroni Group Limited is an Australia-based international biopharmaceutical company. The Company is engaged in the commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. It is engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. Its diversified portfolio is comprised of virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. It operates in Australia, United States, China and Japan. Its products offering include NicoBloc, CII-ArboViroPlex rRT-PCR assay and stem cell cosmetic products, including AGG Skin-Smoothing and Anti-Wrinkle Facial Mask, ODd Skin Repair Essence, ODd Beroni Beauty Facial Mask, and others.
BERONI GROUP LIMITED 
